SKYE · Insider Trading
Skye Bioscience, Inc. Common Stock
Every open-market purchase and sale reported by SKYE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-24 | Andrew J. Schwab | Director | Sell | −148,079 | −$239.56K |
| 2026-09-24 | Kush Parmar | 10%+ Owner | Sell | −1,184,632 | −$1.92M |
| 2026-09-18 | Andrew J. Schwab | Director | Sell | −33,892 | −$64.73K |
| 2026-09-18 | Kush Parmar | 10%+ Owner | Sell | −271,136 | −$517.87K |
| 2026-08-20 | 5AM CO-INVESTORS II LP | 10%+ Owner | Sell | −3,006,720 | −$1.12M |
| 2026-08-20 | Andrew J. Schwab | Director | Sell | −375,840 | −$140.31K |
| 2026-08-07 | Punit Dhillon | Chief Executive Officer | A | +1,090,000 | — |
| 2026-08-07 | Punit Dhillon | Chief Executive Officer | A | +1,090,000 | — |
| 2026-04-02 | Paul A. Grayson | Director | A | +75,000 deriv. | — |
| 2026-04-02 | Deborah H. Charych | Director | A | +75,000 deriv. | — |
| 2026-04-02 | Andrew J. Schwab | Director | A | +75,000 deriv. | — |
| 2026-04-02 | Karen L. Smith | Director | A | +75,000 deriv. | — |
| 2026-04-02 | Tuan Tu Diep | Chief Operating Officer | MIXED | — | — |
| 2026-04-02 | Annalisa Jenkins | Director | A | +75,000 deriv. | — |
| 2026-04-02 | Christopher Twitty | Chief Scientific Officer | MIXED | — | — |
| 2026-04-02 | Punit Dhillon | Chief Executive Officer | MIXED | — | — |
| 2026-02-09 | Christopher Twitty | Chief Scientific Officer | A | +150,000 deriv. | — |
| 2026-02-09 | Paul A. Grayson | Director | A | +35,000 deriv. | — |
| 2026-02-09 | Tuan Tu Diep | Chief Development Officer | A | +125,000 deriv. | — |
| 2026-02-09 | Puneet S. Arora | Chief Medical Officer | A | +125,000 deriv. | — |
| 2026-02-09 | Andrew J. Schwab | Director | A | +35,000 deriv. | — |
| 2026-02-09 | Punit Dhillon | Chief Executive Officer | A | +280,000 deriv. | — |
| 2026-02-09 | Annalisa Jenkins | Director | A | +35,000 deriv. | — |
| 2026-02-09 | Deborah H. Charych | Director | A | +35,000 deriv. | — |
| 2026-02-09 | Karen L. Smith | Director | A | +35,000 deriv. | — |
| 2026-02-09 | Kaitlyn Arsenault | Chief Financial Officer | A | +125,000 deriv. | — |
| 2025-08-22 | Andrew J. Schwab | Director | Sell | −231,405 | −$800.55K |
| 2025-08-22 | 5AM Ventures VII, L.P. | 10%+ Owner | Sell | −1,851,240 | −$6.40M |
| 2025-02-28 | Kaitlyn Arsenault | Chief Financial Officer | Sell | −43,216 | −$215.75K |
| 2025-02-26 | Karen L. Smith | Director | A | +35,000 deriv. | — |
| 2025-02-26 | Andrew J. Schwab | Director | A | +35,000 deriv. | — |
| 2025-02-26 | Tuan Tu Diep | Chief Development Officer | A | +150,000 deriv. | — |
| 2025-02-26 | Paul A. Grayson | Director | A | +135,000 deriv. | — |
| 2025-02-26 | Annalisa Jenkins | Director | A | +35,000 deriv. | — |
| 2025-02-26 | Deborah H. Charych | Director | A | +35,000 deriv. | — |
| 2025-02-26 | Puneet S. Arora | Chief Medical Officer | A | +38,000 deriv. | — |
| 2025-02-26 | Kaitlyn Arsenault | Chief Financial Officer | A | +150,000 deriv. | — |
| 2025-02-26 | Punit Dhillon | Chief Executive Officer | A | +250,000 deriv. | — |
| 2024-11-20 | Tuan Tu Diep | Chief Development Officer | Sell | −19,574 | −$97.72K |
| 2024-11-19 | Punit Dhillon | Chief Executive Officer | Sell | −82,910 | −$413.92K |
| 2024-11-19 | Paul A. Grayson | Director | Sell | −86,551 | −$432.06K |
| 2024-11-19 | Kaitlyn Arsenault | Chief Financial Officer | Sell | −43,396 | −$216.65K |
| 2024-10-30 | Kaitlyn Arsenault | Chief Financial Officer | A | +125,000 deriv. | — |
| 2024-10-30 | Deborah H. Charych | Director | A | +70,000 deriv. | — |
| 2024-10-30 | Karen L. Smith | Director | A | +70,000 deriv. | — |
| 2024-10-30 | Andrew J. Schwab | Director | A | +70,000 deriv. | — |
| 2024-10-30 | Punit Dhillon | Chief Executive Officer | A | +650,000 deriv. | — |
| 2024-10-30 | Annalisa Jenkins | Director | A | +70,000 deriv. | — |
| 2024-10-30 | Paul A. Grayson | Director | A | +70,000 deriv. | — |
| 2024-10-30 | Tuan Tu Diep | Chief Development Officer | A | +125,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Andrew J. Schwab | Director | 981,269 | $1.54M |
| 5AM Ventures VII, L.P. | 10%+ Owner | 202,630 | $318.13K |
| Punit Dhillon | Chief Executive Officer | 178,646 | $280.47K |
| 5AM CO-INVESTORS II LP | 10%+ Owner | 175,070 | $274.86K |
| Kush Parmar | 10%+ Owner | 114,851 | $180.32K |
| Paul A. Grayson | Director | 43,243 | $67.89K |
| Kaitlyn Arsenault | Chief Financial Officer | 26,318 | $41.32K |
| Tuan Tu Diep | Chief Operating Officer | 10,282 | $16.14K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SKYE quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.